McKesson's $13B Carve-Out: Private Equity's Deepening Stake in America's Health

IRVING, TX – June 02, 2026 – In a move that sends tremors through the foundations of the American healthcare supply chain, McKesson Corporation has officially closed a deal with private equity giant Apollo Global Management. The transaction, a $1.25 billion investment for a minority stake in McKesson’s Medical-Surgical Solutions (MMS) business, is more than just a line item on a balance sheet. It is the first, decisive step in a plan to sever MMS from its parent and launch it as an independent, publicly traded company, valued at a staggering $13 billion.

While the press releases frame this as a “strategic milestone” designed for “long-term growth,” the reality is far more complex. This deal represents a critical juncture where corporate strategy, private equity’s relentless search for returns, and the stability of our nation's healthcare infrastructure collide. It forces us to ask a fundamental question: when a critical piece of the system that delivers everything from bandages to surgical kits is reshaped by Wall Street, who ultimately benefits, and who bears the risk?

A Multi-Billion Dollar Diagnosis

On the surface, the mechanics of the deal are straightforward. Funds managed by Apollo have purchased convertible preferred equity, securing an approximately 13% ownership interest in the MMS business. McKesson, a diversified healthcare behemoth with a market capitalization north of $88 billion, retains majority ownership and operational control for now, and will continue to consolidate MMS’s financials.

But this is merely a prelude. The stated goal is an eventual Initial Public Offering (IPO), transforming MMS from a divisional afterthought into a standalone entity. Apollo’s investment serves two purposes: it injects capital into MMS, and more importantly, it provides a powerful Wall Street endorsement of its value. Apollo, with over a trillion dollars in assets under management, doesn't make small bets. Its involvement signals a belief that MMS, once freed from its corporate parent, can be optimized for significant financial returns.

This “carve-out” strategy is a well-worn page in the corporate playbook. A large, diversified company identifies a segment that is either underperforming or no longer fits its core mission, and spins it off to “unlock value.” The move is often celebrated by investors who prefer the clarity of a “pure-play” company focused on a single line of business.

Shedding Weight for Shareholder Health

To understand McKesson’s motivation, one need only look at its recent performance. The MMS division, responsible for supplying non-acute care settings like physician offices and surgery centers, has been a drag. Representing a mere 3.2% of McKesson's colossal revenue, the unit has posted sluggish growth since 2020, battered by post-pandemic demand shifts and supply chain disruptions.

In the context of McKesson's most recent fiscal report, which saw the company beat earnings-per-share expectations but miss on revenue, the pressure to streamline is immense. Divesting MMS allows the parent company to sharpen its focus on its primary, and far more lucrative, role as one of the nation's leading pharmaceutical wholesalers. One financial analyst described the move as “strategic housekeeping,” allowing McKesson to dedicate its resources to its core profit centers without the distraction of a lower-margin business.

For McKesson, the logic is unassailable: create a leaner, more focused parent company and launch a newly independent, well-capitalized MMS, maximizing value for shareholders on both sides of the transaction. The $1.25 billion cash infusion from Apollo is just the start of a process intended to make both corporate entities more attractive to the market.

The Private Equity Prescription

Apollo's entry into this equation marks a significant escalation in the financialization of the healthcare supply chain. Private equity firms have been acquiring physician practices and hospital chains for years, but their growing interest in the foundational infrastructure of healthcare is a newer, more systemic trend.

Apollo Partner Maxwell David praised MMS’s “critical role in the non-acute care supply chain,” a statement that highlights exactly what makes it so attractive. This isn't a flashy tech startup; it's a vital, deeply embedded part of the healthcare system. Control a piece of the supply chain, and you control a flow of revenue that is as non-discretionary as it gets. People will always need medical supplies.

The private equity playbook is predictable: increase efficiency, cut costs, leverage assets, and prepare for a profitable exit, typically through an IPO or a sale to another company. While Apollo speaks of providing “innovative capital solutions for growth,” critics of private equity involvement in healthcare point to a different track record—one that can involve aggressive cost-cutting, staff reductions, and a focus on short-term financial metrics that may not align with the long-term health of the business or the needs of its customers.

As MMS prepares to become a public company under the influential gaze of Apollo, the pressure to deliver quarterly returns will be immense. The question is whether that pressure will foster innovation and better service, or simply squeeze more profit from an already strained system.

The Ripple Effect in the Exam Room

For the thousands of hospitals, clinics, and independent medical practices that depend on MMS, this corporate restructuring is not an abstract financial maneuver. It will have tangible consequences. An independent MMS, flush with capital and a focused management team, could theoretically become a more nimble and responsive partner, investing in new technologies and improving its distribution network.

However, the alternative is just as plausible. As a standalone public company with a powerful private equity stakeholder, MMS will face intense pressure to expand its profit margins. This could translate into higher prices for essential supplies, changes to delivery schedules, or a reduction in customer service to cut overhead. In a market with few major distributors—where MMS competes primarily with giants like Cardinal Health and Owens & Minor—any shift by a major player has an outsized impact on the buyers, who often have limited alternative options.

Healthcare administrators will be watching closely to see which path the new MMS takes. The independence could be a catalyst for improvement, but it could also signal the beginning of a more transactional, less supportive relationship, where the bottom line takes precedence over the long-standing partnerships that have defined the medical supply industry.

Navigating the Regulatory Maze

While the initial investment from Apollo has cleared its regulatory hurdles, the planned IPO and full separation of MMS will undoubtedly attract scrutiny from federal regulators. The Federal Trade Commission (FTC) and Department of Justice (DOJ) have become increasingly wary of consolidation and financial maneuvering within the healthcare sector.

The healthcare supply chain is considered critical national infrastructure. Any significant change to its structure raises questions about market competition, price stability, and the resilience of the system in a crisis—a lesson learned the hard way during the early days of the pandemic. Regulators will want to understand how an independent MMS, influenced by private equity, will impact market dynamics. Law firm Davis Polk, with its deep antitrust expertise, advised McKesson on the sale, indicating that these potential regulatory challenges were anticipated from the outset.

The road to an IPO is not guaranteed. As McKesson’s own cautionary statements admit, the separation is contingent on market conditions and may not be completed on the current timeline, or at all. Yet, the die has been cast. The decision to bring in Apollo and publicly declare the intention to spin off MMS has fundamentally altered the landscape, setting in motion forces that will reshape a vital corner of the healthcare world for years to come.